"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 6 | 0 | 6 |
| 2018 | 4 | 4 | 8 |
| 2019 | 5 | 2 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy. Am J Health Syst Pharm. 2021 03 31; 78(8):684-688.
-
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019 12; 42(12):2262-2271.
-
[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)]. Rev Med Liege. 2019 Sep; 74(9):488-494.
-
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019 07; 7(7):515-527.
-
Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage. Life Sci. 2019 Aug 15; 231:116538.
-
Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2019 Sep; 56(9):1051-1060.
-
Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide. Diabetes Obes Metab. 2019 06; 21(6):1365-1372.
-
Publicising trial results before peer review. BMJ. 2019 Feb 12; 364:l556.
-
Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 03; 1864(3):326-334.
-
GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol. 2019 Nov - Dec; 60(6):347-351.